ArticleCancers2021
Amputation for Extremity Sarcoma: Indications and Outcomes.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Primary Malignant Tumours of the Proximal Third of the Fibula, from Epidemiology to Treatment: A Systematic Review.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Review
- Understanding Physical Functioning in Patients with Sarcoma After Amputation: Using an International Classification of Functioning, Disability and Health (ICF) Approach.Annals of surgical oncology · 2026Article
- Epidemiology and Prognosis of Patients With Osteosarcoma at Different Primary Sites: A SEER Population-Based Study.Cancer reports (Hoboken, N.J.) · 2026Article
- Secondary Amputation After Failed Limb-Salvage Surgery Shows Comparable Long-Term Oncological Outcomes to Primary Amputation in Extremity Sarcoma: A 5-Year Follow-Up Study.Journal of clinical medicine · 2025Article
- Evaluation of the effect of neoadjuvant chemotherapy on the planned resectability of extremity soft-tissue sarcomas.Bone & joint open · 2025Article
- Review
- Review
- 3D Bioprinting in Limb Salvage Surgery.Journal of functional biomaterials · 2024Review
- Development of Machine Learning Models for Predicting the 1-Year Risk of Reoperation After Lower Limb Oncological Resection and Endoprosthetic Reconstruction Based on Data From the PARITY Trial.Journal of surgical oncology · 2024Article
- Review
- Article
- Limb Amputations in Cancer: Modern Perspectives, Outcomes, and Alternatives.Current oncology reports · 2023Review
- Prognostic Factors in Extremity Soft Tissue Sarcomas Treated with Radiotherapy: Systematic Review of the Literature.Cancers · 2023Review
- Intraoperative Evaluation of Soft Tissue Sarcoma Surgical Margins with Indocyanine Green Fluorescence Imaging.Cancers · 2023Article
- Limb-salvage surgery versus extremity amputation for early-stage bone cancer in the extremities: a population-based study.Frontiers in surgery · 2023Article
- Two simple-to-use web-based nomograms to predict overall survival and cancer-specific survival in patients with extremity fibrosarcoma.Frontiers in oncology · 2022Article
- Impact of Limb Salvage on Prognosis of Patients Diagnosed With Extremity Bone and Soft Tissue Sarcomas.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcomas are rare, malignant tumors of soft tissues or bone. Limb salvage surgery (LSS) is the standard treatment, but amputation is still an option, especially in local recurrence or complications after LSS.
methodsWe retrospectively reviewed indications and oncological outcomes in patients who underwent an amputation. Two groups with either primary amputations (
resultsFive-year LRFS was 84% with 17 (16%) patients developing local recurrence, of which 16 (13%) occurred in group I. Forty-two (28%) patients developed metastatic disease and overall survival at five years was 44%. Overall survival (OS) was the same in both groups. In those group II patients who had a secondary amputation due to LR or insufficient margins after LSS (
conclusionsThis study indicates the worse oncological outcomes with respect to OS of sarcoma patients requiring an amputation as compared to LSS. Patients with primary amputation or those who had a secondary amputation after failed LSS for whatever reason showed the same oncological results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.